Nu-Life Unveils Nu-V3 5.0
On September 17, Nu-Life unveiled Nu-V3 5.0, the technology we are entering the marketplace with in the next few months. Significant advancements in neuroscience, improvement of biocompatible materials for 3D printing, and the advancement of medical grade 3D printing all contributed, making the design, development, and production of this state-of-the-art device.
LSX World Congress and Nu-Life Partner
Nu-Life Solutions and LSX are partnering over the next 24 months to assist in. creating awareness for Nu-V3 as we prepare to enter the market. Nu-Life will assume a leadership role in a number of global events and virtual events, serving as Platinum Sponsor as well as leading several group discussion and roundtables.
Nu-Life Solutions partners with CEO Magazine for 2026 Market Launch
Nu-Life has been approached by, and we have agreed to collaborate with, CEO Magazine. With 14 million readers, CEO Magazine is a great opportunity to showcase Nu-V3 5.0 ju8st as we are entering the market while also beginning to profile our team and associates who will now be instrumental in Nu-V3 reaching its potential.
04
Nu-Life & NASA
One outcome from our Keynote Address at the LSX conference in. September, was a frequest for information regarding NASA's interest in utilizing Nu-V3 in space. NASA is searching for non-invasive and non-pharmaceutical answers and we will present Nu-V3 as a resource.
03
01
02
Nu-Life Operations in Japan
Our partnership with Foxmark and collaboration Juntendo Hospital in Tokyo has take a leap forward, as Phase I clinical has been performed and we now move on to Phase II utilizing our new Nu-V3 5.0 device. After years of preparation for launching Nu-V3 in japan and Asia, we are now ready to showcase Nu-V3 5.0 and create awareness in japan through the Besli Clinic, an arm of Juntendo, and dedicated solely to neuromodulation.
05
Nu-Life launches webcast and webinar series
As an integral part of our LSX and CEO Magazine series for creating awareness and demand for Nu-V3, we are launching our first in a series of webinars dedicated to to neuroscience and the application. of neuromodulation, highlighting the benefits of our non-invasive and non-pharmaceutical approach.
06
Nu-Life CEO headlines the Investival Showcase USA
The Investival Showcase is an opportunity to speak directly to high-level, MedTech investors and strategic partners. This is a great opportunity to prepare for global expansion beginning with Japan and Europe, 2026.
07
LSX World Congress to Coincide with Nu-V3 market launch
As Nu-Life prepares to clear regulatory and after creating awareness and demand early 2026, we will again serve as Platinum Sponsor and Keynote speaker at the LSX World Congress in Europe, march, 2026.
08
From Development to Commercialization - Capitalizing Nu-V3 for market Entry
Nu-Life Solutions launches the Market Entry Offering, An opportunity to participate in the market launch of Nu-V3 globally beginning with the United States, Japan, and Europe in. 2026.
08